

VECTOR BORNE DISEASE

CANNE CANNE CONTRACTOR OF CONTACTOR OF CONTACTOR OF CONTACTOR OF CONTACTOR OF CONTACTO



DR. PETER J. IRWIN

Peter Irwin graduated from the Royal Veterinary College, London University, in 1982 and after practising in the UK for a few years, moved to Australia where he earned a PhD working with canine babesiosis at James Cook University, Townsville, North Queensland. Peter completed a residency in small animal medicine at the University of Melbourne and is a registered specialist in canine internal medicine. Since 1998, Peter has been teaching small animal medicine and conducting research into vector-borne diseases at Murdoch University, Perth, Western Australia, and served as Principal (Dean) of the veterinary school 2014-2018. His current research focuses on tick-associated illness in humans and other animals in Australia.























WHERE IS THE DISEASE MOST LIKELY TO BE FOUND?

Babesiosis occurs in domesticated dogs and wild canids on every continent on earth, with the exception of Antarctica. It is generally considered the most common and widespread of all the canine vector-borne diseases. Canine babesiosis is also called piroplasmosis, when species of *Theileria* parasites are included.

Geography, climate and socioeconomic factors play pivotal roles in delineating the distribution and clinical picture of babesiosis in dogs.

Local transmission of *Babesia* parasites requires a susceptible mammalian host population and a competent tick vector. Clinical disease risk is greatly increased where high densities of dogs are in close contact with all tick life-cycle stages, such as in kennels, shelters and breeding establishments.





WHERE IS THE DISEASE MOST LIKELY TO BE FOUND?

Ticks have evolved within distinct climatic regions, influenced predominately by the effects of temperature and relative humidity, underpinning the geographic distribution of the various *Babesia* species they transmit. Studies investigating canine babesiosis epidemiology report a seasonality to babesiosis in dogs, coinciding with periods of tick activity and greater likelihood of exposure to infected ticks. Reports in recent years have described the emergence of canine babesiosis around the world. Possible explanations for the apparent spread of canine babesiosis include: expansion in the ranges of vector ticks as a result of their spread by travelling dogs returning from endemic areas; climate change; increased veterinarian awareness of exotic disease; and, improved availability and sensitivity of diagnostic tests.





An introduction to the causative agent

Canine babesiosis is a tick-borne, hemotropic disease with the majority of dogs becoming infected as a consequence a tick bite, however dog-to-dog transmission (i.e. bypassing the tick) occurs when the blood of one individual is mixed directly with that of another, as can occur through blood exchanged **during fighting**, via blood transfusions and transplacentally during gestation in an infected dam.

There are currently eleven **piroplasm species** recorded in dogs. *Babesia canis, B. rossi, B. vogeli, B. vulpes, B. conradae* and *B. gibsoni,* are the best recognised and most comprehensively studied forms of canine babesiosis, however, be aware that other species may arise unexpectedly in your area, or present in dogs with travel history.

Piroplasm species in dogs together with their tick vectors and reservoir hosts



Vector

Canine babesiosis is vectored by hard ticks (Ixodidae) of the genera Ixodes, Rhipicephalus, Haemaphysalis and *Dermacentor,* although for some newly described species the vector, life cycle and reservoir hosts are unknown, and in the case of *B. negevi* the vector is suspected to be a soft tick.



Proportion of vectors infected

that were removed from dogs:



🔨 In a survey conducted in Russia, 20.3% of *D. reticulatus* ticks (n = 404) removed from dogs contained *Babesia canis* DNA.



Yet just 1.5% of ticks removed from dogs in the UK were positive for babesial DNA, and only 10% of these were of a species known to cause disease in dogs (B. vulpes).



In Malaysia 1.4% of *R. sanguineus* removed from dogs contained both *B. vogeli* or *B. gibsoni* DNA.

Babesia spp. are transovarially transmitted.

VECTOR BORNE DISEASE

The prevalence of infected ticks varies considerably between locations and tick species, as well as the method of collection. In general, the prevalence of piroplasm DNA is lower in unfed (questing) ticks collected in the environment compared with ticks



Reservoirs

The mammalian reservoir for *Babesia vogeli, B. canis* and *B. gibsoni* is the domestic dog, and these three parasites appear to have evolved and fully adapted to canine companion animals, however transmission of these piroplasms to wild canids may occur from time to time (e.g. *B. vogeli* to dingoes in Australia).

For other *Babesia* (and *Theileria*) species the reverse is true – wild animals maintain the parasite within sylvatic life cycles, and 'spill-over' (i.e. accidental infection) occurs from time to time, presumably when domestic dogs encounter the native tick vector. This situation is analogous to the way that people become infected with zoonotic tickborne infections.

VECTOR BORNE DISEASE

Probability of transmission

Probability of vector-borne transmission increases with:

High densities of dogs and ticks in the same environment Activities that facilitate the exchange of blood between dogs





Transmission mechanics

Tick bite is the common way that dogs become infected and transmission dynamics align with tick life cycles. For the most part, canine babesiosis vectors are 'three-host' ticks, meaning that each life cycle stage (larvae, nymphs and adults) feed on a different individual mammalian host, detaching and molting prior to their next feed.

Babesia parasites can be transmitted in blood from an infected dog, either through bite wounds or blood transfusions, or transplacentally, although the documented evidence for this varies between species.





Life cycle of the global tick *Rhipicephalus sanguineus*

(7) Adults attach to the third host for feeding and mating

Adult male

6 Nymphs molt into adults after leaving second host









WHAT BEHAVIORS PUT A DOG AT RISK FOR THE DISEASE?



CAN A DOG BE INFECTED AND NOT SHOW SIGNS?



WHAT CLINICAL SIGNS **DOES A SICK DOG SHOW AND WHY?**

Pathogenesis

The severity of babesios ranges from subclinical infections to widespread organ failure and death. Infected animals develop some level of **anemia** and some develop specific organ pathologies. The pathogenicity of canine babesiosis depends on several factors:





C Other factors such as **dog age and immune status**, the presence or absence of co-morbidities (e.g. immunosuppressive states), and presence of other tick-borne infections all contribute to the clinical outcome.





WHAT CLINICAL SIGNS DOES A SICK DOG SHOW AND WHY?

Early signs

Clinical signs of babesiosis are variable in the early (acute) stages of infection, however most dogs will develop lethargy, inappetence, weakness (progressing to collapse and death in some cases), and pallor (pale mucous membranes).



WHAT CLINICAL SIGNS DOES A SICK DOG SHOW AND WHY?

Progression

Depending on the virulence of the organism and its pathogenicity, progression of the clinical picture in dogs that survive the first few days may be mild (i.e. towards recovery) or associated with worsening signs:

Epistaxis in some dogs



Extreme pallor usually with jaundice (icterus) observed in areas of pale skin, in the mucous membranes, and in the sclera of the eyes

Discolored urine (hemoglobinuria or bilirubinuria)



WHAT CLINICAL SIGNS DOES A SICK DOG SHOW AND WHY?

Prognostic factors

Severe babesiosis is characterized by a high mortality, but the prognosis is not necessarily correlated with clinical signs or parasitemia.

Clinicopathologic markers

Acute infections

VECTOR BORNE DISEASE

Recovery indications

Uncomplicated babesiosis, that is dogs without severe metabolic derangements, tend to recover quickly (within 24-48 hours) once their hematocrit is restored to normal through blood transfusion and antibabesial drug therapy.

Signs that indicate recovery include a brighter demeanor, return of appetite, fever reduction (if present), and return of strength.





Rapid, table-side

Highly sensitive and regionallyappropriate molecular (PCR-based) tests can be requested at local pathology laboratories and have significantly improved the diagnostic options available to practitioners.

thorough history is essential. The physical examination should document the associated clinical signs

VECTOR BORNE DISEASE

Diagnostic laboratories

Samples should be collected for hematology, serum biochemistry and urinalysis in all cases of suspected babesiosis.

Specific vector-borne disease panels, which include PCR and serological tests, are available from some commercial laboratories, and babesiosis is usually one of the diseases tested.







In hospital using microscope or similar equipment

Intra-erythrocytic inclusions can be seen in blood smears of dogs with acute babesiosis.

Microscopic evaluation of blood smears from dogs with chronic babesiosis is less likely to be successful given few parasites in the blood, however other important blood cell characteristics may be seen, and this diagnostic step should always be performed.





In hospital using microscope or similar equipment

A good blood smear with minimal artefact (e.g. stain precipitate, contamination) is critical.





Test interpretation

Depending on the species of *Babesia* (and therefore the predominant pathophysiology), one or more organ systems may be affected during acute infection and this will be reflected in the laboratory results. Additionally, secondary injury associated with the inflammatory response, hypoxemia and shock may result in numerous metabolic derangements.







VECTOR BORNE DISEASE



The hemogram usually includes hemolytic anemia, thrombocytopenia and inflammatory leukogram in cases of acute babesiosis.

Plasma total solids/protein measurements are variable; hypoalbuminemia is reported with *B. canis, B. gibsoni* and **B.** vulpes, and a polyclonal gammopathy has been recorded in some cases, associated with hyperglobulinemia.

Serum biochemistry abnormalities reflect respective organ athologies and acid-base disturbances associated with acute infections.



Differential diagnoses

Differential diagnoses should include other causes of acute hemolysis and other causes of systemic inflammatory response syndrome (SIRS) such as acute septicemia.









Acute vs convalescent

Death in complicated cases of babesiosis generally occurs within 24-48 hours after admission, but most cases start to recover soon after the administration of a blood transfusion, supportive fluid therapy, and anti-babesial drugs.

A rapid improvement in hematocrit is observed in dogs starting to recover, and other analytes, except for bilirubin, also quickly return to reference intervals in survivors.

Some dogs remain icteric for a week or more, and this is reflected in elevated bilirubin and orange urine for several days.







Classes of drugs to use

Acute canine babesiosis treatment requires specific management of the metabolic derangements, with blood transfusion(s) and specific anti-babesial drugs.

babesiosis is early identification of the *Babesia* species.



- Treatment protocols for canine babesiosis should not be expected to eliminate the pathogen.
- cannot be recommended.

VECTOR BORNE DISEASE

Anti-babesial drugs encompass aromatic diamidines, naphthoquinones, artemisinin derivatives and antibiotic classes. There are dissimilar drug susceptibilities, and an important consideration for the appropriate treatment of canine

S Despite the worldwide importance of this disease there are relatively few robust studies on anti-babesial drug efficacy.

Combinations of tetracyclines (minocycline and doxycycline), metronidazole, clindamycin and enrofloxacin are used for atovaquone/azithromycin-resistant *B. gibsoni* infections, with variable efficacy. Without further data these combinations



Mono or combination therapy

The efficacy of mono-versus combination drug therapy for canine babesiosis needs further investigation.

Atovaquone/Buparvaquone + Azithromycin

Diminazine aceturate + Imidocarb dipropionate/ Clindamycin/Metronidazole



VECTOR BORNE DISEASE



The best-recognized therapeutic combinations are atovaquone or buparvaquone with the macrolide antibiotic azithromycin for the treatment of B. gibsoni and B. vulpes, respectively.

Other combinations such as diminazine aceturate with imidocarb dipropionate, with clindamycin and/or metronidazole have shown efficacy in a few cases in uncontrolled studies.



Management of co-infections

Co-infections such as monocytic ehrlichiosis and anaplasmosis (*A. platys*) are common, especially with *B. vogeli* and should be treated with doxycycline (10 mg/kg q24h PO x 28 days).







Supportive treatment strategies

Supportive treatment restores adequate tissue oxyge present.

Blood transfusions

Fluid therapy

Oxygen therapy

Good nursing support

Treating tick infestations

VECTOR BORNE DISEASE



Supportive treatment restores adequate tissue oxygenation by correcting anemia, dehydration and electrolyte disturbances, if





Monitoring for response to treatment

Hematocrit, blood gases, electrolytes and renal function should be assessed at least daily during acute infection.







ARE OTHER PETS OR PEOPLE IN THE HOUSE AT RISK?

The risks to people from an infected/sick dog

Babesiosis is not contagious, in the sense that it is not readily transmitted between dogs although parasites may be transmitted through bite wounds (blood exchange). The presence of an infected dog indicates there is a risk to other dogs in the household from tick bite transmission.

Other public health considerations

Canine babesiosis is not known to be zoonotic; although dog owners can face other risks from tick bites.

Can cats get this infection/disease?

No currently recognized agent of canine babesiosis infects cats.



A *Babesia* parasite closely related to *B. canis* (sensu lato) may infect cats but is a distinct sub-species named *B. canis* subsp. *presentii*.





WHAT ARE SOME RECOMMENDATIONS **AROUND PREVENTION STRATEGIES?** How to avoid the vector Is routine testing recommended?

There are recent remarkable advances in the types and range of acaricidal drugs available, with **new compounds** replacing earlier generations of drugs that were potentially more toxic to the mammalian host.

Increasing owner compliance with treatment recommendations is an important goal in acaricide treatment.

VECTOR BORNE DISEASE

Blood donors

Routine testing for the safety and suitability of dogs to act as blood donors is recommended.

Other animals

Routine testing of other apparently healthy dogs is of no value and chronically infected dogs are difficult to detect, even using PCR. Treatment is not generally curative, therefore routine testing may not offer much value.





WHAT ARE SOME RECOMMENDATIONS AROUND PREVENTION STRATEGIES?

General thoughts on preventive treatments

Regular acaricidal and tick prophylactic treatment is recommended in endemic areas, together with avoidance of dog fighting and pre-screening of blood donors.

Ensuring owner compliance is a key goal for preventive treatment.

Is there a vaccine?

A vaccine for *B. canis* is available in Europe and appears to have reasonable **efficacy for preventing** infection with this form of babesiosis.





WHAT DOES THE FUTURE LOOK LIKE?





FURTHER READING

Bibliography

- S Baneth G, et al. 2004. Infection with a Proposed New Subspecies of Babesia canis, Babesia canis subsp. presentii, in Domestic Cats. Journal of Clinical Microbiology. 42: 99-105.
- S Baneth G. 2018. Antiprotozoal treatment of canine babesiosis. Veterinary Parasitology. 254:58-63.
- **S** Baneth G, *et al.* 2020. A new piroplasmid species infecting dogs: morphological and molecular characterization and pathogeny of Babesia negevin. sp. Parasites and Vectors. 13:130.
- S Barash NR, et al. 2019. Prevalence of Babesia spp. and clinical characteristics of *Babesia vulpes* in infection in North American dogs. Journal of Veterinary Internal Medicine. 33: 2075-2081.
- **S** Dear JD, *et al.* 2017. *Babesia conradae* infection in coyote hunting dogs infected with multiple blood-borne pathogens. Journal of Veterinary Internal Medicine, 32:1609-1617,

- Irwin PJ. 2009. Canine babesiosis: from molecular taxonomy to control. Parasites and Vectors. 2 Supplement 1 S4.
 - Schnittger L, et al. 2012. Babesia: a world emerging. Infection, Genetics and Evolution. 1:1788-1809.
- 🥄 Solano-Gallego L, Baneth G. 2011. Babesiosis in dogs and cats expanding parasitological and clinical spectra. Veterinary Parasitology. 181:48-60.
- Solano-Gallego L, *et al.* 2016. A review of canine babesiosis: the European perspective. Parasites and Vectors. 9:336.
- Wardrop KJ, et al. 2016. Update on Canine and Feline Blood Donor Screening for Blood-Borne Pathogens. Journal of Veterinary Internal Medicine. 30:15-35.
- Wright I. 2018. Babesiosis in Essex: monitoring and learning lessons from a novel disease outbreak. Parasites and Vectors, 11:132.





VECTOR BORNE DISEASE

Copyright © 2020 Intervet International B.V., also known as MSD Animal Health. All rights reserved.



